Brenton Flynn, Motley Fool health care bureau chief, discusses AbbVie. Like other pharmaceutical companies, this company serves a non-cyclical market of consumers that aren't very price-conscious. He then addresses specific advantages that AbbVie enjoys, naming three reasons to buy the stock:

  1. Humira's pipeline -- AbbVie has a tremendous opportunity to serve hepatitis C patients, of whom there are 170 million worldwide.
  2. Concerns about Humira are overdone. Humira is a biologic, which is more difficult to copy than other small molecule drugs.
  3. AbbVie has one of the top dividends among big pharma, sporting a 4% yield.

Follow along in the video below to learn more about each of these reasons you might consider buying AbbVie for your portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.